These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19328713)

  • 1. Identification and functional validation of therapeutic targets for malignant melanoma.
    Gremel G; Rafferty M; Lau TY; Gallagher WM
    Crit Rev Oncol Hematol; 2009 Dec; 72(3):194-214. PubMed ID: 19328713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
    Winnepenninckx V; van den Oord JJ
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.
    Eberle J; Fecker LF; Hossini AM; Kurbanov BM; Fechner H
    Exp Dermatol; 2008 Jan; 17(1):1-11. PubMed ID: 18095940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel genes associated with malignant melanoma but not benign melanocytic lesions.
    Talantov D; Mazumder A; Yu JX; Briggs T; Jiang Y; Backus J; Atkins D; Wang Y
    Clin Cancer Res; 2005 Oct; 11(20):7234-42. PubMed ID: 16243793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel MITF targets identified using a two-step DNA microarray strategy.
    Hoek KS; Schlegel NC; Eichhoff OM; Widmer DS; Praetorius C; Einarsson SO; Valgeirsdottir S; Bergsteinsdottir K; Schepsky A; Dummer R; Steingrimsson E
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):665-76. PubMed ID: 19067971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
    Lorigan P; Eisen T; Hauschild A
    Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
    Koon HB; Atkins MB
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):79-88. PubMed ID: 17187522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival.
    Karst AM; Dai DL; Cheng JQ; Li G
    Cancer Res; 2006 Sep; 66(18):9221-6. PubMed ID: 16982766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine-based therapy for melanoma: pre-clinical studies.
    Shurin MR; Kirkwood JM; Esche C
    Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-221 and -222 pathway controls melanoma progression.
    Felicetti F; Errico MC; Segnalini P; Mattia G; Carè A
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1759-65. PubMed ID: 18983236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
    Alonso SR; Tracey L; Ortiz P; Pérez-Gómez B; Palacios J; Pollán M; Linares J; Serrano S; Sáez-Castillo AI; Sánchez L; Pajares R; Sánchez-Aguilera A; Artiga MJ; Piris MA; Rodríguez-Peralto JL
    Cancer Res; 2007 Apr; 67(7):3450-60. PubMed ID: 17409456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma gene expression and clinical course.
    Vourc'h-Jourdain M; Volteau C; Nguyen JM; Khammari A; Dreno B
    Arch Dermatol Res; 2009 Oct; 301(9):673-9. PubMed ID: 19326132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.